D DAY ONE BIOPHARMACEUTICALS I
| Market Cap | $2.20B |
| P/E Ratio | — |
| Forward P/E | 1141.63 |
| Dividend Yield | — |
| Beta | -1.25 |
| 52W Range | $5.64 - $21.30 |
| # Hedge Funds | 0 |
| Sector | Healthcare |
| Industry | Biotechnology |
Hedge Fund Ownership
| Investor 0 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|
Insider Trading
| Insider Name of the company insider who made the trade 9 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| VASCONCELLES MICHAELHead of Research and Dev. | Sale | 2,728 | $11.60 | $31.65K | 17 Feb 2026 | 18 Feb 2026 |
| Merendino LaurenChief Commercial Officer | Sale | 5,814 | $11.60 | $67.45K | 17 Feb 2026 | 18 Feb 2026 |
| Bender JeremyCHIEF EXECUTIVE OFFICER | Sale | 15,459 | $11.60 | $179.34K | 17 Feb 2026 | 18 Feb 2026 |
| York Charles N IICOO and CFO | Sale | 6,065 | $11.60 | $70.36K | 17 Feb 2026 | 18 Feb 2026 |
| Dubow AdamGen Counsel & Secretary | Sale | 6,395 | $11.60 | $74.19K | 17 Feb 2026 | 18 Feb 2026 |
| Merendino LaurenChief Commercial Officer | Sale | 3,726 | $8.91 | $33.22K | 17 Nov 2025 | 18 Nov 2025 |
| Bender JeremyCHIEF EXECUTIVE OFFICER | Sale | 15,894 | $8.91 | $141.69K | 17 Nov 2025 | 18 Nov 2025 |
| York Charles N IICOO and CFO | Sale | 4,062 | $8.91 | $36.21K | 17 Nov 2025 | 18 Nov 2025 |
| Dubow AdamGen Counsel & Secretary | Sale | 4,319 | $8.91 | $38.50K | 17 Nov 2025 | 18 Nov 2025 |
Frequently Asked Questions
What is DAWN stock price today?
DAY ONE BIOPHARMACEUTICALS I (DAWN) is currently trading at $21.28. The stock has a 52-week range of $5.64 to $21.30 and a market capitalization of $2.20B.
Is DAWN a good stock to buy in 2026?
DAY ONE BIOPHARMACEUTICALS I has a P/E ratio of N/A (forward P/E: 1141.6), a dividend yield of none, and 1-year performance of +163.7%. 0 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling DAWN stock?
There have been 9 insider transactions for DAWN in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has DAWN stock performed over the past year?
DAY ONE BIOPHARMACEUTICALS I (DAWN) has returned +163.7% over the past 12 months. The stock traded between $5.64 and $21.30 during this period, and is currently at $21.28.
Which hedge funds own DAWN (DAY ONE BIOPHARMACEUTICALS I)?
0 tracked hedge funds currently hold DAWN in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is DAWN's market cap and valuation?
DAY ONE BIOPHARMACEUTICALS I (DAWN) has a market capitalization of $2.20B. The trailing P/E ratio is N/A and forward P/E is 1141.6. The stock is classified in the Healthcare sector.
What is DAWN's revenue and profitability?
DAY ONE BIOPHARMACEUTICALS I reported revenue of $158.18M with net income of N/A and a profit margin of N/A. The stock has a beta of N/A.
What sector is DAWN in and who are its biggest institutional holders?
DAY ONE BIOPHARMACEUTICALS I (DAWN) operates in the Healthcare sector. It is held by 0 tracked hedge funds. See the ownership table above for the complete list.